FDASmart will be holding  a one-day forum on "Global Mergers and Acquisitions for the Indian Biopharma Industry: Boom or Bust for the Indian Pharmaceutical Industry?" on June 9 at ITC Grand Central Hotel, Parel, Mumbai.

With Deloitte as knowledge partner and Ranjit Shahani-Novartis MD India as keynote, FDASmart has assembled a world-class group of speakers for this one-day event. Speakers from India will cover the recent concerns from the Indian government regarding Foreign Direct Investment.
 
Some of the topics covered include: How to retain pharma companies cultures after alliances or post-mergers; The truth & realities about financial gain/loss for Indian pharmaceutical mergers and acquisitions; Future of Indian pharmaceutical industry as these alliances with Indian generics pharma continue; How Indian pharma are using demergers to increase market valuation; Impact on domestic Indian healthcare depending on NPPI pricing policy to deflect these mergers & acqusitions; Effects of possible NPPA drug pricing adjustments on the pharmaceutical industry as possible investments and of course the Indian healthcare scenario


For more details contact: Sheela Bathija at 91 98207 51727 or email at sbathija@fdasmart.com / or  Ram Balani at 91 96196 61452 or email at rbalani@fdasmart.com